John McDonough - Amer Renal COO, Executive Vice President Treasurer
President
Mr. John J. McDonough is no longer Chief Operating Officer Executive Vice President Treasurer of the Company effective December 31 2016. Mr. McDonough served on our board of directors from 2012 to August 2015. Mr. McDonough was appointed as our Chief Operating Officer in 2011 and Treasurer in 2012. Prior to being appointed our Chief Operating Officer Mr. McDonough served as our Executive Vice President and Chief Financial Officer from 2003 to 2011. Mr. McDonough has more than 24 years of experience in accounting and finance. Prior to joining our company from 1998 to 2001 Mr. McDonough served as Vice President and Chief Accounting Officer at DaVita Healthcare Partners Inc. Prior to that Mr. McDonough was Chief Financial Officer at Palatin Technologies Inc. from 1995 to 1997 and Chief Financial Officer at MedChem Products Inc. from 1990 to 1995. Previously Mr. McDonough served as audit manager and held other positions at KPMG Peat Marwick since 2015.
| Age | 51 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Phone | 978 922-3080 |
| Web | www.americanrenal.com |
Amer Renal Management Efficiency
The company has Return on Asset of 4.35 % which means that on every $100 spent on assets, it made $4.35 of profit. This is considered to be average in the sector. In the same way, it shows a return on shareholders' equity (ROE) of 17.51 %, implying that it generated $17.51 on every 100 dollars invested. Amer Renal's management efficiency ratios could be used to measure how well Amer Renal manages its routine affairs as well as how well it operates its assets and liabilities.The company has 724.51 M in debt with debt to equity (D/E) ratio of 3.94, meaning that the company heavily relies on borrowing funds for operations. Amer Renal Assoc has a current ratio of 1.03, demonstrating that it is in a questionable position to pay out its financial commitments when the payables are due. Debt can assist Amer Renal until it has trouble settling it off, either with new capital or with free cash flow. So, Amer Renal's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Amer Renal Assoc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Amer to invest in growth at high rates of return. When we think about Amer Renal's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Robert Long | The Coca Cola | 61 | |
| Catherine Suever | Parker Hannifin | 60 | |
| Beatriz Perez | The Coca Cola | 54 | |
| John Wright | Constellation Brands Class | 56 | |
| William Bowman | Parker Hannifin | 62 | |
| Jimes Sabia | Constellation Brands Class | 58 | |
| Alfredo Rivera | The Coca Cola | 60 | |
| Thomas Gentile | Parker Hannifin | 48 | |
| Henry DeVuono | Brandywine Realty Trust | 49 | |
| Thomas Wirth | Brandywine Realty Trust | 57 | |
| Reinald Siswanto | Vita Coco | 33 | |
| Alexander Cummings | The Coca Cola | 58 | |
| Robert Hanson | Constellation Brands Class | 61 | |
| Jennifer Mann | The Coca Cola | 51 | |
| Kurt Keller | Parker Hannifin | 58 | |
| Jared Fix | Constellation Brands Class | N/A | |
| Donny Hartanto | Vita Coco | 37 | |
| William Eline | Parker Hannifin | 61 | |
| James Sabia | Constellation Brands Class | 62 | |
| Claudia Lorenzo | The Coca Cola | N/A | |
| Martin Maxwell | Parker Hannifin | 61 | |
Management Performance
| Return On Equity | 17.51 | |||
| Return On Asset | 4.35 |
Amer Renal Assoc Leadership Team
Elected by the shareholders, the Amer Renal's board of directors comprises two types of representatives: Amer Renal inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amer. The board's role is to monitor Amer Renal's management team and ensure that shareholders' interests are well served. Amer Renal's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amer Renal's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jason Boucher, Chief Accounting Officer, Vice President - Finance, Treasurer | ||
| Steven Silver, Independent Director | ||
| Patrick Ryan, Independent Director | ||
| Thomas Erickson, Independent Director | ||
| John Jureller, Independent Director | ||
| Jonathan Wilcox, CFO, Vice President | ||
| Michael Costa, Vice President General Counsel, Secretary | ||
| Robert Fish, Independent Director | ||
| Joseph Carlucci, Chairman of the Board, Chief Executive Officer, Co-Founder | ||
| Jeremy Gelber, Independent Director | ||
| Don Williamson, Chief Operating Officer, Executive Vice President | ||
| Christopher Hocevar, Independent Director | ||
| Syed Kamal, President, Co-Founder, Director | ||
| Jared Hendricks, Independent Director | ||
| John McDonough, COO, Executive Vice President Treasurer | ||
| Michael Boxer, Independent Director | ||
| Susanne Clark, Independent Director | ||
| Mark Herbers, Interim Chief Financial Officer, Interim Chief Accounting Officer |
Amer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amer Renal a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 17.51 | |||
| Return On Asset | 4.35 | |||
| Profit Margin | (1.11) % | |||
| Operating Margin | 9.73 % | |||
| Current Valuation | 1.26 B | |||
| Shares Outstanding | 34.54 M | |||
| Shares Owned By Insiders | 9.15 % | |||
| Shares Owned By Institutions | 80.77 % | |||
| Number Of Shares Shorted | 608.63 K | |||
| Price To Earning | 144.04 X |
Pair Trading with Amer Renal
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amer Renal position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amer Renal will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Baxter International could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Baxter International when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Baxter International - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Baxter International to buy it.
The correlation of Baxter International is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Baxter International moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Baxter International moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Baxter International can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Other Consideration for investing in Amer Stock
If you are still planning to invest in Amer Renal Assoc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Amer Renal's history and understand the potential risks before investing.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |